COPENHAGEN, Denmark and SEATTLE, May 2, 2011 /PRNewswire/ — CMC
Biologics, a leading biopharmaceutical Contract Manufacturing
Organization, with operations in Copenhagen, Denmark and Seattle,
Washington USA, announced today that it has hired Claes Glassell to
serve at its Chief Executive Officer. CMC Biologics, a company with
370 employees, is committed to delivering world class, fully
integrated, biopharmaceutical process development and manufacturing
Claes Glassell brings more than 30 years of industry experience
to CMC, most recently as CEO of Cerus Corporation and prior to that
as President of Cambrex Corp.
“We are thrilled that Claes has joined the CMC executive team,”
said David Kauffmann, Chairman of the Board, CMC Biologics, and
Managing Director of European Equity Partners. “Claes has been on
CMC’s board of directors for more than 5 years, and has during that
time exhibited a broad range of experience and insight of our
industry. Claes’ strong leadership qualities and seasoned business
understanding makes him the ideal leader to take CMC Biologics to
the next level as a leader in our fast moving industry.”
“Joining the CMC Executive team at this important time in the
Company’s lifecycle is a great privilege,” said Claes Glassell.
“The Company has, despite a very challenging environment in recent
years, been successful in continuing to realize strong growth.
Today, CMC has a very solid order book demonstrating the strength
of the Company’s world class service offering, management and
science team. CMC is positioned to be a highly successful
Claes Glassell joined the CMC board of directors in 2005. Claes
left the position as President & CEO of Cerus Corporation, Inc.
to take on the position as CEO of CMC Biologics. He is the former
President of Cambrex Cor